Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of empagliflozin/linagliptin on oxidative stress markers in chronic kidney disease patients with type 2 diabetes (stage 3)
TCTR20210322002Phase 4Completed
- Sponsor
- N/A
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, linagliptin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by N/A. Started Jul 2020; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on TCTR20210322002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210322002.